Alkermes reports positive Phase 1b data for ADHD drug ALKS 7290Sep 21Clinical readoutAlkermes, Inc.ALKS-7290
Alkermes registers Phase 2 trial of ALKS 7290 for adult ADHDAug 10Trial updateAlkermes, Inc.ALKS-7290
Alkermes names Blair Jackson CEO, effective August 1, as pipeline milestones nearJul 28Quarterly updateAlkermes, Inc.ALKS-7290
Sign inSign in